1. Home
  2. SLRX vs NAOV Comparison

SLRX vs NAOV Comparison

Compare SLRX & NAOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Salarius Pharmaceuticals Inc.

SLRX

Salarius Pharmaceuticals Inc.

HOLD

Current Price

$0.78

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Logo NanoVibronix Inc.

NAOV

NanoVibronix Inc.

HOLD

Current Price

$4.02

Market Cap

4.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLRX
NAOV
Founded
N/A
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
4.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SLRX
NAOV
Price
$0.78
$4.02
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
664.7K
31.0K
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,685,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.71
$3.55
52 Week High
$108.00
$162.50

Technical Indicators

Market Signals
Indicator
SLRX
NAOV
Relative Strength Index (RSI) 26.09 43.18
Support Level $0.81 $3.83
Resistance Level $0.89 $4.74
Average True Range (ATR) 0.07 0.45
MACD 0.10 0.07
Stochastic Oscillator 0.00 25.97

Price Performance

Historical Comparison
SLRX
NAOV

About SLRX Salarius Pharmaceuticals Inc.

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

About NAOV NanoVibronix Inc.

NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients, through distributor agreements.

Share on Social Networks: